Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident Type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study

Diabetes Research and Clinical Practice

Volumn 85, Issue 1, 2009, Pages 90-95

  Harati, Hadi ^a   Hadaegh, Farzad ^a   Tohidi, Maryam ^a   Azizi, Fereidoun ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

IFG; Incidence; Type 2 diabetes

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; IRAN; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; REFERENCE VALUE; RISK ASSESSMENT;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY SIZE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FAMILY; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INCIDENCE; IRAN; MALE; MEDICAL HISTORY TAKING; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 67349195457     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.04.006     Document Type: Article

References (23)

1. The Expert Committee on the diagnosis and classification of diabetes mellitus, Report of the Expert Committee on the diagnosis and classification of diabetes mellitus, Diabetes Care 20 (1997) 1183-1197.
2. World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes and Mellitus, World Health Organization, Geneva (publ. no. WHO/NCD/NCS/99.2), 1999.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Follow-up report on the diagnosis of diabetes mellitus, Diabetes Care 26 (2003) 3160-3167.
4. Davidson M.B., Landsman P.B., and Alexander C.M. Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 26 (2003) 3329-3330
5. Borch-Johnsen K., Colagiuri S., Balkau B., Glümer C., Carstensen B., Ramachandran A., et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47 (2004) 1396-1402
6. Vaccaro O., and Riccardi G. Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 28 (2005) 1786-1788
7. Kim S.M., Lee J.S., Lee J., Na J.K., Han J.H., Yoon D.K., et al. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care 29 (2006) 226-231
8. Hadaegh F., Harati H., Ghasemi A., Tohidi M., Zabetian A., Mehrabi Y., et al. Using common clinical data improves the prediction of abnormal glucose tolerance by the new criteria of impaired fasting glucose: Tehran lipid and glucose study. Diabetes Res. Clin. Pract. 77 (2007) 459-464
9. Forouhi N.G., Balkau B., Borch-Johnsen K., Dekker J., Glumer C., Qiao Q., et al., On behalf of EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 49 (2006) 822-827
10. Nichols G.A., Hillier T.A., and Brown J.B. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 30 (2007) 228-233
11. Janghorbani M., Amini M., Willett W.C., Mehdi Gouya M., Delavari A., Alikhani S., et al. First nationwide survey of prevalence of overweight, underweight, and abdominal obesity in Iranian adults. Obesity (Silver Spring) 15 (2007) 2797-2808
12. Hadaegh F., Bozorgmanesh M.R., Ghasemi A., Harati H., Saadat N., and Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 8 (2008) 176
13. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., et al., American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 (2007) 753-759
14. Azizi F., Rahmani M., Emami H., Mirmiran P., Hajipour R., Madjid M., et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study phase 1. Soz. Praventivmed. 47 (2002) 408-426
15. Roger N. Parameters behind "nonparametric" statistics: Kendall's tau, Somers' D and median differences. STATA J. 2 (2002) 45-64
16. Unwin N., Shaw J., Zimmet P., and Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. 19 (2002) 708-723
17. Shaw J.E., Zimmet P.Z., Hodge A.M., de Courten M., Dowse G.K., Chitson P., et al. Impaired fasting glucose: how low should it go?. Diabetes Care 23 (2000) 34-39
18. Gabir M.M., Hanson R.L., Dabelea D., Imperatore G., Roumain J., Bennett P.H., et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23 (2000) 1108-1112
19. Ryu S., Shin H., Chang Y., Sung K.C., Song J., and Lee S.J. Should the lower limit of impaired fasting glucose be reduced from 110 mg/dL in Korea?. Metabolism 55 (2006) 489-493
20. Valdés S., Botas P., Delgado E., Alvarez F., and Cadórniga F.D. Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study. Metabolism 57 (2008) 399-403
21. Schriger D.L., and Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic?. Diabetes Care 27 (2004) 592-601
22. Farjadian S., Ota M., Inoko H., Ghaderi A., The genetic relationship among Iranian ethnic groups: an anthropological view based on HLA class II gene polymorphism. Mol Biol Rep. 2008 Nov 2. [Epub ahead of print].
23. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159 (2004) 882-890